Capricor Therapeutics, Inc.
Deramiocel
Duchenne muscular dystrophy cardiomyopathy
Date
TBD
Approval decision · Date TBD estimated
What's at stake
A final FDA approval decision on Deramiocel for Duchenne muscular dystrophy cardiomyopathy is expected Date TBD.
Primary source
· SEC 8-K
verified 15h ago
“the FDA has lifted the previously issued Complete Response Letter (“CRL”) and resumed review of its Biologics License Application (“BLA”) seeking full approval of Deramiocel, an investigational cell therapy, for the treatment of Duchenne mu”